IL1B and cancer: Next, the repurposed use of advanced therapies is discussed, to finally comment the roadblocks and challenges for anti-IL-1ß and anti-CD20 repurposed strategies in cancer and CVD, and the lessons learned for improved therapies, including the relevance of biomarker-driven stratification and treatment of patients.